Lonza
↗Basel, Switzerland
Lonza is a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotechnology, and nutrition markets. Founded in 1897 in the Swiss Alps, the company has evolved from a small electricity and chemical producer into a multinational powerhouse that provides integrated healthcare solutions. Lonza specializes in the development and manufacturing of a wide range of therapeutic modalities, including small molecules, biologics, cell and gene therapies, and bioconjugates.
The company operates through a newly streamlined 'One Lonza' organizational structure comprising three main business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Lonza is a critical partner in the global pharmaceutical supply chain, famously known for its large-scale production of the active ingredient for Moderna's mRNA COVID-19 vaccine. In 2024, the company announced a strategic shift to exit its Capsules & Health Ingredients (CHI) business to focus exclusively on its core CDMO offerings.
CLASSIFICATION
SIZE & FINANCIALS
Employees:10000+
Revenue:$7.2B (CHF 6.6B)
Founded:1897
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:BlackRock, Inc., UBS Fund Management (Switzerland) AG
STOCK
Exchange:SIX Swiss Exchange
Ticker:LONN
Market Cap:$47.4B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb, ADC, Cell therapy, Gene therapy, mRNA, Microbial
Active Trials:660
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Capsugel, Synaffix, Lonza Walkersville, Inc., Lonza Houston, Inc.
Key Partnerships:Moderna (mRNA vaccine manufacturing), Vertex Pharmaceuticals (Casgevy manufacturing), Roche (Acquisition of Vacaville site and long-term supply), AstraZeneca (Biologics manufacturing), Kodiak Sciences (ADC manufacturing)
COMPETITION
Position:Leader
Competitors:Catalent, WuXi AppTec, Samsung Biologics, Thermo Fisher Scientific, Fujifilm Diosynth Biotechnologies, Siegfried Holding
LEADERSHIP
Key Executives:
Wolfgang Wienand - CEO
Jean-Marc Huët - Chairman
Philippe Deecke - CFO
Board Members:Jean-Marc Huët (Chair), Roger Nitsch, David Meline, Claudia Süssmuth-Dyckerhoff, Barbara Richmond
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Lonza. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.